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Abstract. Many guidelines for prevention and treatment still locate persons in risk 
classes (e.g. low, moderate, high) on the basis of thresholds placed on a continuous 
metric for a single criterion (e.g. risk of developing x). These ‘traffic light’ signals 
can lead to inferior decisions through their mono-criterial focus and lack of 
preference-sensitivity to the multiple criteria relevant to the person. It is arguably 
unethical to communicate to someone that they are at low, moderate, or high risk of 
x solely on the basis of the unpublished and often unknown preferences of the 
group that has set the classification thresholds. Any prior classification and 
labelling will interfere with the individual’s balanced processing of information on 
the performance of all treatment options on their multiple relevant criteria - 
including treatment side effects and burdens as well as main benefit - and 
jeopardise meeting the requirements for fully informed and preference-based 
consent to any subsequent action. Personalised decision support tools based on 
Multi-Criteria Decision Analysis can help fulfil these objectives, with apomediative 
(at home) e-decision support especially appealing because of its empowering and 
resource-saving potential. The individual’s absolute risk score is required in these 
tools since any threshold-based risk classification will interfere with the coherence 
of the analysis across the multiple criteria. 
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Introduction 
 
Guidelines for the prevention and treatment of many conditions locate persons in risk 
classes (stereotypically the ‘traffic lights’ of low, moderate, and high) on the basis of 
cut-offs placed on a continuous scale. Sometime the original source of these thresholds 
is lost in time and cannot now be identified; they have simply become normalised and 
are used because data based on them exist and can be analysed.  
 
Many thresholds have no discernible analytical basis and are presented as the 
consensus of a group of experts, usually exclusively or mainly clinicians from the topic 
area. For example, the NICE guidelines for breast cancer triage the chance of a 40-50 
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 year old developing breast cancer into   >3% = ‘near population level risk’; 3%-8% = 
‘moderate risk’; >8% = ‘high risk’ [1].  No explanation is published for adopting these 
particular thresholds, though frequently NICE refers to its thresholds as resulting from 
the Guidance Development Group’s ‘taking various considerations into account’. In 
prostate cancer, total PSA levels of 4.0 ng/ml and 10.0 ng/ml are typically used as 
triaging thresholds, again without any explicit analytical basis [2]. Some thresholds 
have a purely statistical basis, such as parameter values on a single-criterion 
distribution. Bone fragility guidelines invariably follow this practice, natural since 
osteoporosis is statistically-defined. A Bone Mineral Density of -2.5 standard 
deviations below the mean of a young US female constitutes osteoporosis. Other 
thresholds are based in whole or part on single-criterion cost-effectiveness analysis. For 
example, the National Osteoporosis Guidelines Group (NOGG) guidelines 
(https://www.sheffield.ac.uk/NOGG/downloads.html) use Frax-based age-specific 
thresholds derived from cost-effectiveness analyses [3]. 
 
The number of guidelines which eschew formal risk classification and promote the 
use of the individual’s unclassified absolute risk is increasing. The 2015 update of the 
Joint British Societies guidelines on primary prevention of cardiovascular disease [4] is 
notable in its replacement of the traffic lights of 2005 [5] with the ‘continuum of risk’ 
concept. However, they still have difficulty abstaining from referring to patients as 
‘high risk’ ‘elevated risk’ or ‘increased risk’ and JBS3 still refers to an intervention 
threshold. The provenance of these thresholds is not, however, the focus here. It is their 
use in person-centred care, including and especially their communication to the person. 
Their use in research and population-level management is an entirely separate question. 
 
The heart disease example we draw on later relates to cholesterol and statins: 
 
LDL (low-density lipoprotein cholesterol, also called "bad" cholesterol) …  can 
increase your chances of getting heart disease…The lower your LDL cholesterol 
number, the lower your risk. If your LDL is 190 or more, it is considered very 
high. Your doctor will most likely recommend a statin in addition to making 
healthy lifestyle choices…You may also need to take a statin even though your 
LDL level is lower than 190. After figuring your 10-year risk, your doctor will 
recommend a percentage by which you should try to lower your LDL level through 
diet, exercise, and medication if necessary. [ https://www.webmd.com/cholesterol-
management/guide/understanding-numbers#1] 
 
In summary, looking across conditions, we can find no analytical basis for any 
particular thresholds (e.g. 10%, 15%, 20%) and resulting risk characterisations other 
than population-level effectiveness and cost-effectiveness analyses. Evidence-based in 
any other sense, most are not. While possibly appropriate at the policy level, this makes 
them inappropriate in person-centred care or clinical practice guidelines.  
 
‘Traffic light’ risk classifications can cause considerable harm by their mono-criterial 
focus and lack of preference-sensitivity (completely appropriate as preference-
insensitivity is on the road). The communication of risk class to the individual person 
 
  interferes with their decisional autonomy, and the possibility of unbiased 
personalised, preference-sensitive, multi-criterial decision making, by pre-
emptive psychological framing  
 hinders the giving and obtaining of the person’s legally required informed and 
preference-based consent to any provider action, since the required unbiased 
personalised assessment of all harms and benefits has not been undertaken.  
 
To give their informed and preference-based consent to any test or treatment, the 
person must be informed about the harms and benefits of all the relevant options, with 
the magnitudes of those harms and benefits being assessed on the basis of their 
personal importance weights at or near the point of decision. While this requirement is 
rarely fully met today (except in surgery) it will be a prominent feature of the future 
we envisage [6]. A key implication is that it is not acceptable to focus on the single 
outcome proposed as the main criterion, e.g. CVD in the heart case, fracture in the 
bone health case, Cancer in oncology. The decision process must address the other 
considerations that matter to the person - equally as seriously and equally as 
analytically. When combined with the requirement for the individual to be able to 
weight those criteria explicitly and transparently, one is driven towards some form of 
multi-criteria analysis personalised decision support tool [7]. The use of a mono-
criterion, threshold-based guideline, based on average patients, becomes suspect. 
 
Among the many obstacles to the provision of absolute risks are mistaken provider 
and professional beliefs that risk classifications aid risk communication by 
simplification. But traffic light risk communication invariably goes beyond 
straightforward simplification of the risk assessment, to imply that a particular action – 
stratified risk management or mitigation - should follow. Since any decision requires 
value-based preference judgments to be combined with risk assessment, 
communicating a risk class based on a mono-criterial risk assessment will inevitably 
contaminate the multi-criterial preference elicitation required for risk management. 
 
It is well known that labelling, such as being at ‘high risk’ can have stigmatising 
and/or disabling effects. But what if the person actually seeks a definitive label to 
eliminate unwanted and troubling uncertainty about their health? Unfortunately, in 
many situations, providing a diagnosis, as supposed to a probabilistic differential 
diagnosis, represents ethically suspect mis-information. The prognoses will almost 
always be uncertain, and the person is therefore presented with a confusing mix of an 
apparently certain diagnosis and set of uncertain prognoses under alternative 
therapeutic options. The focus should be on the latter in person-centred care. 
 
Methods 
 
Thresholds are, by definition, based on particular value judgments, so that clinicians 
following threshold-based guidelines are unwittingly imposing the preferences of some 
group at the time they were set or confirmed. The implied trade-offs between the 
screening/test and treatment errors at guideline thresholds are most unlikely to match 
those elicited from any individual person. For informed and preference-based decision 
making and consent, the person requires the best estimates available for the sensitivity, 
 specificity, and population-relevant Predictive Values Positive and Negative at their 
specific result. In principle, they require them for All-cause mortality, for Condition-
specific mortality, and for Condition-specific development. 
 
Since providing all this data to the person is likely to be more overpowering than 
empowering, the good news is that thresholds and labels are no longer needed. The 
person can receive – or should be able to receive – personalised decision support based 
on their specific individual absolute result. A personalised decision support tool 
(PDST) based on Multi-Criteria Decision Analysis (MCDA) will hold the above data 
for all possible test results and can produce scores for all the management options - 
without provider censoring - given a specific test result.  
 
The type of MCDA most compatible with ethical person-centred decision making 
and most able to ensure informed and preference-based consent is the value-based, 
compensatory model. This takes the form of a ‘weighted-sum’ calculation, which 
multiplies the personalised numerical ratings for the performance of each option on 
each criterion by the relative weight assigned to the criterion by the person, and then 
sums these weighted scores to get an overall preference-sensitive score for each option. 
The performance ratings for all options on all criteria must be on the same continuous 
0-1 (0 to 100%) scale and be personalised to the absolute risk of the individual 
concerned. Any segmented classification of an absolute risk for any criterion will 
undermine cross-criterial comparability and hence the coherence of the analysis.  
 
Inter-mediative Personalised Decision Support Tools (PDSTs) - often called 
Shared Decision Making Support Tools or Patient Decision Aids - are designed to help 
the clinician and patient decide together, in their encounter, what is best for the 
patient. Apomediative PDSTs are a ‘direct-to-citizen’ e-health resource designed to 
help the person decide what is best for themselves, including whether to seek a health 
service consultation and/or to prepare for, and engage in, a hybrid apo-intermediative 
consultation [8]. These apomediative tools are analogous to the comparison websites 
for goods and services now proliferating on the internet, but with individual criterion 
weighting. Insofar as they contain an uncensored set of options and commit to the 
personalised assessment of benefits and harms of all these, apomediative support tools 
help ensure that the key requirements of self-produced health are met, along with 
legally informed and preference-based consent to any subsequent provider action. The 
clinician will very often become involved in the making of the supported decision 
subsequently, not only because they have greater relevant knowledge (e.g. ability to 
identify some contraindications), but also because only they have the power to order a 
test, prescribe a medication or refer for, or undertake, surgery.  
 
Result 
 
A brief illustration of an apomediative  PDST is provided here for the statin decision: 
Should I go, or not go, to my general practitioner to discuss taking statins?  To engage 
with the tool, go to https://goo.gl/H7P51r.  Figure 1 is an illustrative screen capture for 
a 60 year old male smoker with a systolic blood pressure of 160 and a total cholesterol 
 of 5. This example is hypothetical and has no empirical claims to be a properly 
developed and validated decision support tool. 
 
 
 
Figure 1. Final screen capture for Statin decision, with  
   pre-entered and supplied Ratings and Weightings 
 
The PDST involves the person: completing an online instrument to obtain an 
estimate of their personalised risks of All-Cause and Cardiovascular Mortality in the 
next ten years; self-assessing their blood pressure and total cholesterol level, which are 
the two inputs required, along with age, sex and smoking status, to complete the 
EuroSCORE-based instrument; self-rating the treatment burden of statins (in respect of 
burden ratings there may also be inputs from significant others, such as family and 
other carers, or caregivers if in a cared-for facility); and assigning relative importance 
weights to the four criteria (10 year mortalities, statin side effects and statin burden).  
 
The PDST includes All-Cause Mortality as well as CVD mortality, because the 
authors of the underlying paper rightly stress that exclusive use of a condition-specific 
cause of mortality (such as CVD), gives the misleading impression that the person is 
immortal if they do not die from that condition [9]. Most published papers which report 
the effect of alternative options on multiple criteria can be the basis of an MCDA-based 
PDST, making them an excellent vehicle for the translation of research findings into 
‘bedside’ decision making. (Numerous examples are provided at 
http//:www.cafeannalisa.org.uk.) 
 
Discussion 
 
It should be noted that person-centred care does not mean that the person simply 
gets what is optimal for them in a personalised decision support tool. Even if they agree 
with the opinion of the tool, the person is also a citizen – one person among many other 
 persons – and cost-effectiveness is therefore a valid principle. However, it must not be 
disguised within risk characterisations, as it is when individuals are said to be at ‘high 
risk’ only when it is cost-effective to treat them (e.g. in relation to bone fragility). The 
person is respected as a person and as a citizen only when they are given the honest - 
and justifiable - reason for any restriction on option availability. 
The aim of this paper is strictly limited. It seeks only to provide proof of method that 
online decision support tools based on the technique of Multi-Criteria Decision 
Analysis (MCDA) can meet both the ethical requirements for person-centred care and 
the legal requirements for consent. And to argue that this can and should be done 
without reference to thresholds or classifications imposed on continuous risk measures 
for a single criterion. 
 
Conclusion 
 
Risk classifications may be helpful, even essential, to researchers developing the 
probabilistic prognoses for treatment options that are required inputs for an MCDA-
based PDST. However, these labels are not needed in person-centred care and mono-
criterion-based risk classification labelling may do more harm than good.  
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